192 related articles for article (PubMed ID: 8625134)
1. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study.
Burdach SE; Müschenich M; Josephs W; Frisch J; Schulz G; Jürgens H; Göbel U
Cancer; 1995 Aug; 76(3):510-6. PubMed ID: 8625134
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.
Wexler LH; Weaver-McClure L; Steinberg SM; Jacobson J; Jarosinski P; Avila N; Pizzo PA; Horowitz ME
J Clin Oncol; 1996 Mar; 14(3):901-10. PubMed ID: 8622038
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children.
Saarinen-Pihkala UM; Lanning M; Perkkiö M; Mäkipernaa A; Salmi TT; Hovi L; Vettenranta K
Med Pediatr Oncol; 2000 May; 34(5):319-27. PubMed ID: 10797353
[TBL] [Abstract][Full Text] [Related]
4. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors.
van Pelt LJ; de Craen AJ; Langeveld NE; Weening RS
Pediatr Hematol Oncol; 1997; 14(6):539-45. PubMed ID: 9383806
[TBL] [Abstract][Full Text] [Related]
6. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony stimulating factor (rh-GM-CSF) in the treatment of chemotherapy-induced neutropenia.
Gözdasoglu S; Unal E; Yavuz G; Pamir A; Reisli I; Deda G; Tarcan A; Babacan E; Cavdar AO
J Chemother; 1995 Oct; 7(5):467-9. PubMed ID: 8596135
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia.
Saarinen UM; Hovi L; Riikonen P; Pihkala J; Juvonen E
Med Pediatr Oncol; 1992; 20(6):489-96. PubMed ID: 1435519
[TBL] [Abstract][Full Text] [Related]
9. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery.
Fink FM; Maurer-Dengg K; Fritsch G; Mann G; Zoubek A; Falk M; Gadner H
Med Pediatr Oncol; 1995 Nov; 25(5):365-71. PubMed ID: 7545780
[TBL] [Abstract][Full Text] [Related]
15. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
17. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
19. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]